A Survey of Maribavir Tablets in Participants With Cytomegalovirus Infection

Takeda

Status

Enrolling

Conditions

Cytomegalovirus (CMV)

Treatments

Drug: Maribavir

Study type

Observational

Funder types

Industry

Identifiers

NCT06577363

jRCT2031240302 (Registry Identifier)

TAK-620-4013

Details and patient eligibility

About

This study is a survey in Japan of Maribavir tablets used to treat participants with Cytomegalovirus (CMV) infection refractory to existing anti-CMV therapy in organ transplantation (including hematopoietic stem cell transplantation).

The main aim of the study is to check if treatment with Maribavir can protect Japanese people against CMV infection, and to check side effect from the study treatment. The study sponsor will not be involved in how the participants are treated but will provide instructions on how the clinics will record what happens during the study.

During the study, participants with CMV infection will take Maribavir tablets according to their clinic's standard practice. The study doctors will check for side effects from Maribavir tablets for 27 weeks.

Enrollment

250 estimated patients

Sex

All

Volunteers

No Healthy Volunteers

Inclusion criteria

- All participants with Cytomegalovirus (CMV) infection refractory to existing anti-CMV therapy in organ transplantation (including hematopoietic stem cell transplantation).

Exclusion criteria

- None